June 29, 2004

Skinvisible Granted U.S. Patent on Polymer-Based Delivery System for Skincare Delivery System

LAS VEGAS, Jun 29, 2004 /PRNewswire-FirstCall via COMTEX/ --

Skinvisible, Inc. (OTC Bulletin Board: SKVI) Website: (www.skinvisible.com) announced through it's wholly owned subsidiary Skinvisible Pharmaceuticals, Inc. that it has received notice from the United States Patent and Trademark Office that its patent application for "Topical Composition, Topical Composition Precursor, and Methods For Manufacturing And Using" has issued as U.S. Patent Number 6,756,059.

The patent is directed at manufacturing topical polymer-based delivery system compositions and includes disclosure of various "Topical Compositions and Methods for Manufacturing and Using the Compositions." A divisional application is pending, directed at "Topical Composition and Methods for Using the Composition." The Company has registered the name "Invisicare(R)" to identify the fifteen different polymer compositions it has developed to date.

When topically applied, products incorporating "Invisicare(R)" adhere to the skin's outer layers forming a protective bond that resists both wash-off and perspiration for extended periods of time, while delivering targeted levels of active ingredients to the skin. Utilizing its technologies, the Company has developed and tested antibacterial/antimicrobial hand sanitizers, skincare moisturizers, sunscreens, sunless tanners, acne, psoriasis, eczema, tooth whitener and other topical OTC formulations.

Terry Howlett, the Company's President, states, "This will greatly assist our customer base of both Cosmetic and Pharmaceutical companies in offering protection for their proprietary products."

"Of significant note," says Skinvisible(R) Chemist and Inventor, Dr. James Roszell, "is that Invisicare(R) offers distinct advantages for drug delivery over conventional creams and ointments." Invisicare(R) offers enhanced skin adherence due to sustained drug delivery for longer periods of time.

Headquartered in Las Vegas, Nevada, Skinvisible, Inc. is focused on the development of innovative topical polymer-based delivery systems and related technologies incorporating its patent-pending formula/process for combining hydrophilic and hydrophobic polymers into stable water emulsions. Skinvisible's(R) primary marketing and sales objectives are to license its technologies and/or sell its delivery systems to provide enhanced product performance for established brand manufacturers and providers of prescription, over-the-counter, cosmetic and skincare products. In addition, Skinvisible(R) formulates and manufactures products for private label customers.

This press release contains "forward looking" statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934 as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports that will be on file with the US Securities and Exchange Commission (including but not limited to the report on Form 10-KSB for the quarter ending March 30, 2004).

For further information, please contact: T. Howlett of Skinvisible, Inc., +1-702-433-7154, or fax, +1-702-433-7192, terry@skinvisible.com; or Media, Tommi Hanley of Thompson Lloyd Communications, +1-250-860-9959, tommi.tlc@shaw.ca, for Skinvisible, Inc.

Press Release Index

New Press Release Alerts:

If you are interested in receiving corporate and new product development news from Skinvisible, simply enter your email address below.